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Abstract
Background: Epithelial-mesenchymal transition (EMT) is a crucial step for solid tumor progression and plays an
important role in cancer invasion and metastasis. RNF8 is an ubiquitin E3 ligase with RING domain, and plays essential
roles in DNA damage response and cell cycle regulation. However the role of RNF8 in the pathogenesis of breast cancer
is still unclear.
Methods: The expression of RNF8 was examined in different types of breast cell lines by Western Blotting. EMT
associated markers were examined by Immunofluorescence and Western Blotting in MCF-7 when RNF8 was ectopically
overexpressed, or in MDA-MB-231 when RNF8 was depleted. Transwell and wound healing assays were performed to
assess the effect of RNF8 on cell mobility. The xenograft model was done with nude mice to investigate the role of RNF8
in tumor metastasis in vivo. Breast tissue arrays were used to examine the expression of RNF8 by immunohistochemistry.
Kaplan-Meier survival analysis for the relationship between survival time and RNF8 signature in breast cancer was done
with an online tool (http://kmplot.com/analysis/).
Results: RNF8 is overexpressed in highly metastatic breast cancer cell lines. Overexpression of RNF8 in MCF-7 significantly
promoted EMT phenotypes and facilitated cell migration. On the contrary, silencing of RNF8 in MDA-MB-231 induced
MET phenotypes and inhibited cell migration. Furthermore, we proved that these metastatic behavior promoting effects
of RNF8 in breast cancer was associated with the inactivation of GSK-3β and activation of β-catenin signaling. With nude
mice xenograft model, we found that shRNA mediated-downregulation of RNF8 reduced tumor metastasis in vivo. In
addition, we found that RNF8 expression was higher in malignant breast cancer than that of the paired normal breast
tissues, and was positively correlated with lymph node metastases and poor survival time.
Conclusions: RNF8 induces EMT in the breast cancer cells and promotes breast cancer metastasis, suggesting that RNF8
could be used as a potential therapeutic target for the prevention and treatment of breast cancer.
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Background
Breast cancer (BC) is the most invasive form of cancer in
women and is the second leading cause of cancer death in
industrial nations [1]; the incidence rate of the disease has
been rising in many countries [2]. Advanced breast cancer
is associated with significant mortality because it metasta-
sizes to vital organs. Tumor metastasis is a multistage
process, among which epithelial-mesenchymal transition
(EMT) is believed to be an initial step, during which non-
motile, polarized epithelial cells lost their cell-cell junc-
tions and converted into individual, non-polarized, motile
and invasive mesenchymal cells [3, 4]. EMT can be in-
duced or regulated by various growth and differentiation
factors, including TGF-β, Wnt and Notch, as well as the
tyrosine kinase receptor pathway [5, 6]. Activation of these
pathways leads to transcriptional repression of a series of
target genes that are involved in epithelial maintenance,
including CDH1 gene, leading to the functional loss of
E-Cadherin, one of the well-known hallmarks of EMT.
The disappearance of E-Cadherin from adherent junc-
tions results in the release of β-catenin into cytosol,
and subsequent translocation to the nucleus where it
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can activate LEF/TCF (lymphoid enhancer factor/T cell
factor)-mediated transcription, induce the expression of
Snail, Slug and Twist [7], thereby contributing to the
EMT program. Therefore, EMT is a cellular repro-
grammed process that involves multiple layers of regu-
lation for the gene transcription, including epigenetic
regulation such as the post-transcriptional modification
mediated by histone methylation and acetylation or
deacetylation, as well as protein ubiquitination. It is as-
sumed that many enzymes participated these processes
are also important EMT regulators and play essential
role in tumor metastasis [8, 9].
RNF8 is an ubiquitin E3 ligase with two conserved
domains: the N-terminal FHA (Forkhead-Associated)
and the C-terminal RING (Really Interesting New
Gene) domain. The FHA can specifically bind phospho-
peptides motif (pTXXF) in the target proteins [10, 11],
while the RING is responsible for its E3 ligase activity.
In response to DNA damage, gammaH2AX is phos-
phorylated, followed by the binding and subsequent
phosphorylation of MDC1. This phosphorylation of
MDC1 leads to the phosphorylation-dependent recruit-
ment of RNF8 to the sites of DNA double strand breaks
(DSBs), where RNF8 binds to the E2, Ubc13, and catal-
yses the formation of lysine 63-linked polyubiquitin
chains (K63-Ubs) on histones [12–14]. The ubiquitination
of histones at DSBs provides a structural chromatin plat-
form for the subsequent recruitment of key DNA damage
repair proteins such as 53BP1 and BRCA1, the latter of
which is a well-known tumor suppressor, mutation of
which strongly predisposes women to breast cancer
[15–19]. In addition to the synthesis of K63Ubs, RNF8
can also catalyze the formation of K48-linked ubiquitin
chains when coupled with other conjugating E2s such
as UBCH8, UBE2E2, UbcH6, and UBE2E3 [20–24].
These RNF8-mediated K48-linked ubiquitin degrada-
tions play an important role in the control of protein
abundance or turnover of many players, for example,
JMJ2A and Ku80, which are involved in the DNA dam-
age response (DDR) [22, 23].
In addition to its critical role in DDR, RNF8 is also im-
plicated in many other biological processes, such as
spermatogenesis, telomere end protection, mitosis and
apoptosis [25, 26]. High-level amplification of RNF8 in
lung cancer and leukaemia cells was revealed by the
Cancer Genome Project (Sanger Institute) [27], but the
role of RNF8 in tumorigenesis, especially in breast can-
cer metastasis remains poorly defined.
Here we report that RNF8 is overexpressed in
highly metastatic breast cell lines and its overexpres-
sion can induce EMT in breast cancer cells. Further-
more, RNF8 is aberrantly expressed in invasive breast
cancer and positively correlates with lymph node
metastasis.
Results
RNF8 is overexpressed in malignant breast cancer cell
lines
To determine the role of RNF8 in breast cancer, we first
examined its expression in breast cell lines with various
differentiated character by western blotting, including
the immortalized breast cell lines MCF-10A and MCF-
10 F, the epithelial breast cancer cell lines MCF7 and
T47D, and the metastatic, mesenchymal breast cancer
cell lines MDA-MB-231 and BT549, as well as MDA-
MB-435, a breast metastasis-derived cell line of melan-
oma origin. Quantitative analysis of the Western blotting
results was performed by normalizing the density of
RNF8 band to that of β-actin. As shown in Fig. 1, the ex-
pression of RNF8 was increased in MCF7 (2.0-fold), and
significantly elevated in T47D (7.3-fold), MDA-MB-231
(6.0-fold), BT549 (5.0-fold) and MDA-MB-435 (9.9-fold),
as compared with the expression of RNF8 in MCF-10A
and MCF-10 F, suggesting that the expression of RNF8
positively correlated with the metastatic potential of
breast cancer cell lines.
RNF8 induces EMT of breast cancer cell line
Epithelial-mesenchymal transition has been considered
to be one of the critical steps involved in cancer metas-
tasis [4, 6, 28]. Core elements of EMT include reduction
of cell–cell adherence via the transcriptional repression
and delocalization of cadherins, and functional loss of E-
Cadherin is a well-known hallmark of EMT. Expression of
epithelial intermediate filaments is typically reduced and
the equivalent mesenchymal filament protein vimentin in-
creased. To investigate what role, if any, RNF8 might play
in the EMT, the morphological alterations and epithelial
or mesenchymal marker changes in RNF8-expressing
MCF-7 cells were assessed by microscopy and western
blotting, respectively. As shown in Fig. 2a (upper panel),
while control MCF-7 cells maintained organized cell–cell
adhesion, overexpression of RNF8 in MCF-7 cells by lenti-
viruses infection led to loss of cell–cell contacts; and these
cells became scattering and gain a variable cell shape.
In agreement with this, immunofluorescent microscopy
showed a significant reduction or loss of E-cadherin
staining in the cell membrane of RNF8-expressing
MCF-7 cells compared with that of control cells (Fig. 2a,
bottom panel). Consistently, overexpression of RNF8 in
MCF-7 cells resulted in reduction of epithelial markers
E-cadherin, and induction of mesenchymal marker fibro-
nectin and snail (Fig. 2b). These results indicate that over-
expression of RNF8 promotes EMT in MCF-7 cells.
Whether depletion of RNF8 could induce MET, a reverse
process of EMT, was also investigated in metastatic breast
cancer cell line MDA-MB-231, using two individual small
interference RNAs against RNF8 (siRNF8-1 and siRNF8-2).
As shown in Fig. 2c, while control cells exhibited a typical
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spindle-like fibroblastic morphology, RNF8-depleted cells
displayed a cobble stone-like appearance. Consistently, im-
munofluorescent microscopy showed a significant reduc-
tion in Vimentin staining in RNF8-depleted MDA-MB-231
cells as compared with that of the control cells (Fig. 2c, left,
bottom panel). Immunoblotting showed that the protein
level of Vimentin and snail was also decreased, while in-
creased expression of E-caderhein, an epithelial marker,
was detected in the cells depleted of RNF8 (Fig. 2d). Fur-
ther examination of transcription of E-cadherin mRNA by
quantitative real-time PCR (qPCR) showed that depletion
of RNF8 in MDA-MB-231 cells indeed resulted in a dra-
matic increase in the transcription of E-caderhein gene
(Additional file 1: Figure S1). Taken together, these results
indicate that overexpression of RNF8 induce mesenchymal
phenotypes, while depletion of RNF8 induce epithelial-like
phenotypes of breast cancer cells, suggesting that RNF8
play an important role in EMT program.
Overexpression of RNF8 inactivates GSK-3β and increases
the accumulation of β-catenin
Glycogen synthase kinase-3 beta (GSK-3β) is a serine/
threonine kinase, plays an important role in the initiation,
progression and malignancy of many cancers [29, 30]. β-
catenin is a crucial effector in EMT, which is phosphory-
lated by GSK-3β that targets it for ubiquitination and
proteosomal degradation. Upon inhibition of GSK-3β, β-
catenin accumulates in the cytoplasm and translocates
into the nucleus, acting as a cofactor for the transcription
factor LEF/TCF, affecting the transcription of genes that
regulate EMT [31–33] including Snail. The activity of
GSK-3β can be inhibited by activated Wnt-pathway or by
PI3K/Akt-mediated phosphorylation at Ser9 of GSK-3β.
We have found that the phospholation of GSK-3β (Ser9)
is increased in RNF8-overexpressing MCF-7 cells. Con-
sistently, the phospholation of β-catenin at Ser33/37/
thr47, which is catalyzed by GSK-3β, is decreased, whereas
the total β-catenin level is slightly increased in MCF-7 cells
overexpressing RNF8 (Fig. 3a). In line with this, the phos-
pholation of GSK-3β is decreased, while the phospholation
of β-catenin is increased in RNF8-depleted MDA-MB-231
cells, stably expressing a small hairpin RNA against RNF8
(Fig. 3b). These data suggest that activation of β-catenin
signaling is involved in RNF8 induced EMT.
RNF8 enhances the cell migration potential of breast
cancer cells
Mesenchymal cells are associated with malignant proper-
ties, such as migration and invasion. To dissect the roles
of RNF8 in EMT, RNF8 was either overexpressed in
MCF-7 cells, or depleted in MDA-MB-231cells, and the
role of RNF8 on the migration potential of these cells was
investigated using transwell and wound healing assays. As
shown in Fig. 4a, the cell migration potential was signifi-
cantly elevated by 2.7 fold in RNF8-overexpressing MCF-7
cells (Fig. 4a, upper panel), while dramatically decreased
to 1/4-1/6 fold of the control in RNF8-depleted MDA-
MB-231 cells (Fig. 4a, bottom panel, and b). Taken to-
gether, these data demonstrate that RNF8 promotes cell
migration in breast cancer cells.
RNF8 promotes breast cancer metastasis in vivo
To further investigate the role of RNF8 in breast cancer
metastasis in vivo, MDA-MB-231 cells that stably express
firefly luciferase (MDA-MB-231-Luc-D3H2LN, Xenogen
Corporation) were transfected with control or RNF8
shRNA to generate stable cell lines. The effect of RNF8 on
tumor metastasis was assessed in immune-compromised
female BALB/c mice (n = 6) by tail vein injection of MDA-
MB-231-Luc-D3H2LN cells. The dissemination of tumors
was monitored weekly by quantitative bioluminescence
imaging with the IVIS imaging system (Xenogen), and a
metastatic event was defined as any detectable luciferase
signal above background. The results showed that the
Fig. 1 RNF8 is overexpressed in invasive breast cancer cell lines. a RNF8 protein expression in immortalized breast cell lines (MCF-10A and MCF-10 F),
non-metastatic breast cancer cell lines (MCF7 and T47D), and metastatic breast cancer cell lines (MDA-MB-231, MDA-MB-435 and BT549), was detected
by Western blotting. β-actin was used as an internal standard. b Quantitative analysis of the Western blotting bands shown in a
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lung metastasis was dramatically decreased in mice
implanted with MDA-MB-231-Luc-shRNF8 cells as
compared with that of the MDA-MB-231-Luc-Control
(Fig. 5a). Metastatic tumor foci in the lungs were con-
firmed by H&E staining. As shown in Fig. 5b, there are
about 2–20 micrometastatic foci formed in each lung
from the mice implanted with MDA-MB-231-Luc-Con-
trol cells; strikingly, only 0 or 5 micrometastatic foci
was found in each lung from the mice injected with
MDA-MB-231-Luc-shRNF8 cells. Moreover, HE stain-
ing also showed that the volume of metastatic foci
seemed much smaller in animals injected with shRNF8
Fig. 2 RNF8 regulates EMT in breast cancer cells. a Overexpression of RNF8 induced EMT in MCF7. MCF7 cells were infected with TG006 (empty
vector with GFP) or TG006-RNF8 virus, the morphological change and the expression of E-Cadherin were examined 5 days later by IMC (upper) or
by indirect immunofluorescence (bottom), using anti-E-cadherin antibody (red, E-cadherin; blue, DAPI). b Expression of the indicated EMT markers
in the infected MCF-7 cells was detected by Western blotting. β-actin was used as an internal standard. c MDA-MB-231 cell lines were transiently
transfected with 20nM siRNA (siControl or siRNF8-1), morphology of the transfected cells were examined 72 h later by IMC (upper), and the expression of
mesenchymal marker was detected by indirect immunofluorescence (bottom) using anti-vimentin antibody (red, vimentin; blue, DAPI). d Expression of
the indicated EMT markers in the infected MDA-MB-231 cells was detected by Western blotting. β-actin was used as an internal control. Magnification,
40 ×; bar: 5 μm
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Fig. 3 RNF8 inactivates GSK3β and increases β-catenin accumulation. a Western blotting analysis of EMT signaling hallmarks in MCF-7 cells infected
with TG006 or TG006-RNF8 virus. β-actin was used as an internal standard. Quantification of each indicated protein expression was plotted (right panel).
The result is shown from three independent experiments (Columns, mean; Bars, ± s.d. ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns, no significance).
b Western blotting analysis of EMT signaling hallmarks in MDA-MB-231 stable cell line expressed control (shRNA empty) or shRNF8-1 or shRNF8-2,
β-actin was used as an internal standard. Quantification of each indicated protein expression was plotted in right panel (right panel). The result is shown
from three independent experiments (Columns, mean; Bars, ± s.d. ***, p< 0.001; **, p< 0.01; *, p < 0.05; ns, no significance)
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cells than that in control cells (Fig. 5b). Metastatic nod-
ules in the lungs were found in five of the six control
group mice (5/6), but only in one of the six shRNF8
group mice (1/6) (Fig. 5c); these data provided further
evidence that RNF8 promotes breast cancer metastasis
in vivo.
It should be noted that the expression of RNF8 and E-
cadherin, as well as the migration potential in MDA-
MB-231-Luc-shRNF8 and MDA-MB-231-Luc- Control
cells were detected to select the positive clones (Fig. 5d).
Before injection, the bioluminescence signals of MDA-
MB-231-Luc-shRNF8 and MDA-MB-231-Luc-Control
cells were also measured to make sure the cells used for
implantation had the same luminescence intensity and
activities (Additional file 1: Figure S2).
RNF8 expression is associated with metastasis in human
breast tumors
To further support the role of RNF8 in promoting
tumor metastasis, the expression of RNF8 was examined
by IHC in breast cancer and the normal adjacent tissues,
using tissue microarray. The histological diagnosis was
Fig. 4 RNF8 promotes cell migration in breast cancer. a The migration of MCF-7 cells infected with TG006 or TG006-RNF8 virus (upper; magnification, 10 ×)
or MDA-MB-231 cells transfected by siControl or siRNF8-1 (bottom; magnification, 20 ×) were examined by transwell migration assay. Overexpression of
RNF8 enhances the migration of MCF-7 cells. **, p< 0.01. The data represent the means ± s.d. of three independent experiments. bWound healing scratch
assay was performed to detect the migration of RNF8-depleted MDA-MB-231 cells described in A. magnification, 10 ×; Right, the relative migration rate
was calculated by dividing the change in the distance between the scratch edges by the initial distance, ***, p <0.001
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Fig. 5 (See legend on next page.)
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made by pathologists according to the standard shown
in Additional file 1: Table S1. The immunostaining pat-
tern was divided into negative, low and high, according
to the score based on total staining intensity and pro-
portion of positive cells. The representative images
were shown in Additional file 1: Figure S3. The expres-
sion of RNF8 was upregulated in breast cancers when
compared with normal adjacent tissues (Fig. 6). Of the
36 cases examined, 18 (50.0 %) showed significant
higher expression of RNF8 in the cancerous tissues
when compared with the corresponding adjacent nor-
mal tissues; while another 16 (44.4 %) showed similar
level of expression in both tissues; only 2 (5.6 %) dis-
played a reverse expression pattern, in which RNF8 ex-
pression was lower in the cancer tissues than that of
normal adjacent ones. Statistical analysis showed a
(See figure on previous page.)
Fig. 5 shRNA-mediated downregulation of RNF8 inhibits tumor metastasis in vivo. a Bioluminescence images in vivo. A total of 1 × 106 /0.1 mL MDA-
MB-231-luc cells stably expressing shRNF8-2 or an empty vector control were injected into caudal vein of 6–8 week-old female BALB/c mice (n = 6)
(left), lung metastases were quantified using bioluminescence imaging. Lungs were harvested via necropsy 43 days after caudal vein injection and were
examined by in vitro bioluminescent measurement (right). b Representative images of hematoxylin and eosin staining of lung sections. (magnification,
4 ×, left; 40 ×, right). Metastatic nodules were indicated by green arrows. c The number of mice with metastatic nodules in the lung sections. d Before
injection, the expression of RNF8 and E-Cadherin in MDA-MB-231-luc-siCon and MDA-MB-231-luc-shRNF8-2 cells were examined by Western blotting
Fig. 6 RNF8 is frequently upregulated in breast bancer tissues. a Expression of RNF8 was examined by IHC in primary breast cancers (Malignant)
and the paired adjacent normal tissues (NAT). b RNF8 is differentially expressed in primary malignant breast cancer tissue compared with the
corresponding paired adjacent normal tissue. For each case of the 36 patients, index of RNF8 expression (immunostaining score of IHC) of the
primary tissue was subtracted by that of the corresponding paired adjacent normal tissue, and the resultant values (Malignant-NAT) from all 36
cases were used for plotting. The relative RNF8 expression level between primary cancer and paired adjacent tissue of each case was represented
as a dot. RNF8 is considered to be significantly upregulated, similar or negative in primary tissue when compared with the corresponding paired
adjacent tissue only if the calculated index is >0 (red dots), 0 (green dot), <0 (blue dots), respectively
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significant increased expression of RNF8 in cancer tis-
sues (P = 0.006). This result indicates that RNF8 is aber-
rantly higher expressed in malignant breast cancer
issues.
To determine whether the up-regulation of RNF8 pro-
tein correlates with breast cancer metastasis, the expres-
sion of RNF8 was further detected by IHC in the primary
cancer tissues and the paired metastatic lymph node. The
histological diagnosis was made by pathologists according
to the standard shown in Additional file 1: Table S1. The
localization of RNF8 was depicted as cytoplasm or nuclear.
The immunostaining pattern was divided into negative,
low and high according to the score based on total staining
intensity and proportion of positive cells; representative
immunostaining pattern were shown in (Additional file 1:
Figure S3). Of the 98 cases examined, 28 cases (28.6 %)
showed higher cytoplasmic expression, 12 cases (12.2 %)
showed higher nuclear expression in the lymph node me-
tastases as compared with the corresponding primary can-
cers; the representative images were shown in Fig. 7a.
However, another 50 cases (51.0 %) with cytoplasmic
RNF8 expression and 28 cases (28.6 %) with nuclear RNF8
expression showed no significant difference between both
tissues; a lower expression pattern in the lymph nodes was
also observed in 11 of the cases (11.2 %) with cytoplasmic
RNF8 expression, and 3 (3.1 %) cases with nuclear RNF8
expression, respectively; complete loss or negative expres-
sion of cytoplasmic or nuclear RNF8 was also observed in
9 (9.2 %) and 55 (56.1 %) cases, respectively (Fig. 7b).
The expression level of RNF8 either in cytoplasm or in
nuclear is significantly higher in lymph node metastases
when compared with the corresponding primary can-
cers (p = 0.014, p = 0.016, respectively). These data sug-
gest a positive correlation between expression of RNF8
and breast cancer metastasis.
We also analyzed the association between RNF8 ex-
pression and the clinic pathological parameters in breast
cancer. As shown in Table 1, there was no significant
correlation between the RNF8 expression levels and the
parameters, including histological grade, clinical stage,
and TNM.
To further extend our observations to a clinicopathologi-
cally relevant context, we performed Kaplan-Meier survival
analysis of RNF8 with an online tool (http://kmplot.com/
analysis/). The results showed that higher RNF8 expression
was associated with a worse overall survival (OS, P = 0.035),
worse Relapse Free Survival (RFS, P = 0.013), and worse
Distant Metastasis Free survival (DMFS, P = 0.00056) of
breast cancer patients, while there was no significant differ-
ence in Post Progression Survival (PPS) of breast cancer pa-
tients (P = 0.16) (Fig. 8), when the influence of systemic
treatment, endocrine therapy, and chemotherapy was ex-
cluded. These data suggest that RNF8 could be used as a
potential predictor of survival.
Discussion
Epithelial-mesenchymal transition plays an important role
in cancer invasion and metastasis, triggered by a diverse
set of stimuli that can lead to stable reprogramming of epi-
thelial cells to mesenchymal states. Here, we identify RNF8
as a novel factor involved in EMTand breast cancer metas-
tasis. We have found that RNF8 is overexpressed in highly
metastatic breast cell lines. Overexpression of RNF8 in-
duces EMT in breast cancer cells, promotes breast cell
migration and tumor metastasis in mouse xenograft model.
Importantly, the expression of RNF8 is up-regulated in
breast cancers tissues and is positively correlates with
lymph node metastasis, establishing an important role for
RNF8 in breast cancer metastasis.
RNF8 is an ubiquitin E3 ligase, localizes primarily to the
nucleus during interphase; whereas under genotoxic stress
(eg. IR treatment), RNF8 is localized to the sites of DNA
damage, where it functions to ubiquitinate many chroma-
tin substrates, including histone H2A, H2AX and H1 that
are crucial for chromatin structure remodeling [11–14]. In
addition, RNF8 also localizes at cytoplasm, especially upon
some special stimuli (eg. stimulated by Human T lympho-
tropic virus type 1 (HTLV-1) trans-activator/oncoprotein,
Tax), plays important roles in cell fate decision or genome
stability through RNF8-mediated K-63 ubiquitination [34,
35]. In this study, we have found RNF8 protein expression
is significantly higher in primary cancers than that of the
matched noncancerous tissues. More importantly, a rela-
tively larger proportion of either cytoplasmic or nuclear
expression of RNF8 is higher in lymph node metastases
than in the corresponding primary cancers. Overexpres-
sion of RNF8 led to the decrease of E-Cadherin, a hall-
mark of EMT, and RNF8 induced EMT is associated with
the inactivation of GSK-3β and the accumulation of β-
catenin. β-catenin is a critical player in the EMT signaling
through shuttling from cytoplasm to nuclear, where it ac-
cumulates and complexes to TCF/LEF-1 to activate the
downstream target genes involved in EMT [36–38]. These
results reveal a strong association of RNF8 expression
with EMT and breast cancer metastasis, raising the ques-
tion on how RNF8 induces EMT signaling activation, and
whether the increased expression in cancer cells is linked
to an altered or disturbed RNF8 function, which in turn
might contribute to the initiation and development of
breast cancer. Further study will be needed to answer
these questions.
Some metastasis-associated proteins are also import-
ant DNA damage response regulators, and hence con-
tribute to IR/ anti-cancer drug resistance. One example
is metastasis-associated protein 2 (MTA2), a subunit of
the nucleosome-remodeling and histone deacetylation
(NuRD) chromatin-remodeling complex. Depletion of
MTA2 led to accumulation of spontaneous DNA damage
and increased IR sensitivity [39]. RNF8 is one of the most
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important DNA damage repair molecules, playing cru-
cial roles in DDR. Loss of RNF8 function can sensitize
cells to both IR and DNA damage-inducing agents in-
cluding anti-cancer drugs [11, 40]. One of the most dif-
ficult problems in the treatment of cancer is cancer
metastasis and anti-drug resistance. Since RNF8 is ab-
errantly expressed in many breast cancer patients and
facilitates tumor metastasis, and is a key player in the
DDR pathway, it is therefore a promising target for
anti-cancer therapy. By targeting RNF8, scientists could
kill two birds with one stone in the future: not only the
metastatic potential of cancer cells could be suppressed
or eliminated, but also the efficacy of anti-cancer drugs
could be significantly improved due to the increased
sensitivity of cancer cells to anti-cancer drugs upon
RNF8 depletion.
Fig. 7 RNF8 expression is associated with breast cancer metastasis. a Representative examples showing higher RNF8 expression in the lymph node
metastases than in the corresponding primary breast cancer tissues. case 1, cytoplasmic expression of RNF8; case 2, nuclear expression of RNF8.
Magnification, 20 ×; scale bars: 20 μm; Inset, 40 ×. b Comparison of the RNF8 expression between breast cancer tissues and the corresponding lymph
node metastases. LN > Bre, LN < Bre, and LN = Bre indicate RNF8 expression is higher, lower, or equal in metastatic lymph node compared with that of
primary breast cancer; ‘Both negative’ means that the expression of RNF8 was not detectable in both metastatic lymph node and primary breast
cancer tissues. The histographs show the percentage of cases with distinct expression pattern of cytoplasmic (Left) or nuclear (right) RNF8
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Conclusions
In summary, RNF8 induces EMT in breast cancer cell
line, and knock down of RNF8 reduces tumor metastasis
in nude mice xenograft model. The expression of RNF8
is up-regulated in breast cancers tissues, positively corre-
lates with lymph node metastasis and inversely corre-
lates with survival time of the breast cancer patients.
These findings highlight the potential of RNF8 as a
therapeutic target of breast cancer.
Methods
Cell lines and culture
Human embryonic kidney HEK-293 T, Breast epithelial
cell lines MCF-10A, MCF-10 F, MCF7, T47D and meta-
static breast cancer cell lines MDA-MB-231, MDA-MB-
435 and BT549 were purchased from American Type
Culture Collection (ATCC) and preserved in our labora-
tory, MDA-MB-231-luc was a gift from Dr. Yongfeng
Shang (Peking University Health Science Center). These
cell lines were cultured in medium supplemented with
10 % FBS at 37 °C with 5 % CO2 in a humid atmosphere.
Plasmid construction, siRNA and antibodies
TG006 is a lentiviral empty vector with GFP. For con-
struction of TG006-hRNF8, full-length cDNA encoding
RNF8 was amplified by PCR with Phusion DNA polymer-
ase and subcloned into TG006. siRNA oligonucleotides
(Invitrogen) were synthesized: siRNF8-1 (5′-GGACAAUU
AUGGACAACAA-3′); siRNF8-2 (5′UGCGGAGUAUGA
AUAUGAA-3′). Lentiviral vector shRNF8-1 (the same
sequence with siRNF8-1: 5′-GGACAAUUAUGGACAAC
AA-3′, named as 26620), shRNF8-2 (5′-ACATGAAGCC
GTTATGAAT-3′) and empty vector CONO77 were pur-
chased from GeneChem. The following antibodies were
used: mouse anti-RNF8 (sc-271462; Santa Cruz Biotech-
nology, Inc.); rabbit anti-E-cadherin (#3195, Cell Signaling
Technology); rabbit anti-phospho-β-catenin (Ser33/37/
thr47) (#9561, Cell Signaling Technology); rabbit anti-β-
catenin (#8480, Cell Signaling Technology); rabbit anti-
snail (#3879, Cell Signaling Technology); Monoclonal
anti-Vimentin (V6389, sigma); rabbit anti-actin (sc-1616-
R; Santa Cruz Biotechnology, Inc.); rabbit anti-phospho-
GSK3β (Ser9) (#9336, Cell Signaling Technology); rabbit
anti-GSK3β (#9315, Cell Signaling Technology).
Transfection and infection
Lipofectamine RNAi MAX and Lipofectamine 2000 re-
agent (Invitrogen) were used for transient knockdown by
siRNA or transient overexpression, respectively. All exper-
iments were performed according to the manufacturer’s
instructions. Lentiviral particles were produced by trans-
fecting HEK293T cells with the TG006 vector or TG006-
RNF8, as well as the psPAX2 and pMD2.G packaging
vectors. 8 ug/ml polybrene was used for lentivirus infec-
tion of MCF7 cells and MDA-MB-231 cells.
Protein extraction and western blotting
Immunoblotting was carried out to analysis the protein
expression. Cells were lysed in RIPA buffer containing
protease inhibitor cocktail and phospho-stop (Roche,
Basel, Switzerland). Protein concentrations were deter-
mined using Bradford protein assays. Whole cell ly-
sates were then fractionated using 8–10 % SDS–PAGE
and electrotransferred onto polyvinylidene difluoride
membranes (Millipore Corp., Bedford, MA, USA). The
membranes were then probed with the indicated anti-
bodies, and the immunoreactive bands were developed
using an ECL detection system (Millipore, Billerica,
Table 1 Association of RNF8 expression and clinical pathological features
Variables N RNF8-cytoplasmic N (%) P RNF8-Nuclear N (%) P
Negative Low score High score Negative Low score High score
- + ++ - + ++
Grade 0.658 0.659
1, 2 31 6 (19.4) 19 (61.3) 6 (19.4) 18 (58.1) 10 (32.3) 3 (9.7)
3 49 9 (18.4) 34 (69.4) 6 (12.2) 29 (59.2) 20 (40.8) 0 (0)
Stage 0.299 0.527
II (A + B) 62 13 (21.0) 40 (64.5) 9 (14.5) 35 (56.5) 26 (41.9) 1 (1.6)
III (A + B + C) 33 3 (9.1) 25 (75.8) 5 (15.2) 22 (66.7) 8 (24.2) 3 (9.1)
TNM-T 0.848 0.511
T1 + T2 83 16 (19.3) 54 (65.1) 13 (15.7) 50 (60.2) 30 (36.1) 3 (3.6)
T3 + T4 14 2 (14.3) 11 (78.6) 1 (7.1) 10 (71.4) 3 (21.4) 1 (7.1)
TNM-N 0.874 0.953
N0 + N1 69 13 (18.8) 47 (68.1) 9 (13.0) 44 (63.8) 24 (34.8) 1 (1.4)
N2 + N3 27 5 (18.5) 18 (66.7) 4 (14.8) 18(66.7) 6 (22.2) 3 (11.1)
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MA, USA). All experiments were repeated for three
times. For quantification, the grey density of the tar-
get bands in the immunoblot was analyzed by Image
J software (National Institutes of Health, Bethesda,
Maryland, U.S.) and normalized to the grey density of
β-actin.
Quantative realtime PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen) and cDNA was synthesized using SuperScript II
Reverse Transcriptase (Invitrogen). Quantitative PCR
was performed using an ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). E-cadherin
amplification was performed using the following
primers: 5′- TGGGCTGGACCGAGAGAGTTT-3′ and
5′-CGACGTTAGCCTCGTTCTCAG-3′. Samples were
run in triplicates, and all samples were normalized against
GAPDH using the comparative Ct method (△△Ct).
Immunofluorescence microscopy
Cells grown on coverslips were fixed in 4 % paraformalde-
hyde at room temperature for 10 min, washed three times
with PBS, blocked with 10 % goat serum at 37 °C for
Fig. 8 RNF8 expression reversely correlates with survival time. Kaplan-Meier survival analysis for the relationship between survival time and RNF8
signature in breast cancer was performed by using the online tool (http://kmplot.com/analysis/). A: RFS, Relapse Free Survival; B: OS, Overall Survival; C:
DMFS, Distant Metastasis Free survival; D: PPS, Post Progression Survival. P-value < 0.05 was considered to be a statistically significant difference
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30 min, incubated at 4 °C with the primary antibodies over-
night, washed extensively and probed with the FITC- and
Rhodamine red–conjugated goat anti–rabbit or anti–mouse
IgG (Jackson ImmunoResearch Laboratories, Inc.) at 37 °C
for 30 min. Coverslips were mounted in VECTASHIELD
Mounting Medium with DAPI (Vector Laboratories).
Cell migration and wound-healing scratch assay
Cell migration was measured according to the ability of
the cells to migrate across a transwell filter (8-μm pores,
Costar, Cambridge, MA, USA).1 × 105 MDA-MB-231 cells
or 2 × 105 MCF7 cells suspended in serum-free DMEM
were added to the upper chamber, and DMEM medium
containing 10 % fetal bovine serum was added to the
lower chamber. After a 20 h (for the siRNA-transfected
cells) or 24 h (for the lentivirus-infected cells) incubation
at 37 °C in a 5 % CO2 humidified atmosphere, the non-
migrated cells were scraped off of the filter using a cotton
swab and the cells that migrated to the lower side of the
upper chamber, were fixed with 4 % paraformaldehyde
and stained with hematoxylin. The cells per microscopic
field (MDA-MB-231 cells, 20×; MCF7 cells, 10×) were
taken pictures and counted in 8 randomly chosen fields.
Triplicate wells were performed in each assay, and the
assay was repeated at least three times.
One day before scratch, MDA-MB-231/RNAi cells were
trypsinized and seeded equally into six-well tissue culture
plates and grew to reach almost total confluence in 24 h.
An artificial homogenous wound was created onto the
monolayer with a sterile 10-ul tip. After scratching, the
cells were washed with serum-free medium. Images of the
cells migrating into the wound were captured at time
points of 0 h and 20 h by inverted microscope (10×), all
the experiments were repeated for at least 3 times.
In vivo metastasis
MDA-MB-231 cells that stably express firefly luciferase
(Xenogen) were infected with lentiviruses carrying con-
trol shRNA (CONO77), shRNF8-2, respectively. These
cells were injected into the lateral tail vein (1 × 106 cells)
of 6–7 week-old female BALB/c mice (n = 6). For bio-
luminescence, IVIS Spectrum Imaging System (Xenogen,
Alameda, CA, USA) was used. Lungs were fixed in for-
malin and embedded in paraffin blocks for slicing into
thin sections. The paraffinized sections were stained
with hematoxylin and eosin (H&E) according to stand-
ard protocols. The stained sections were photographed
using a Leica microscope (Leica, Wetzlar, Germany).
Immunohistochemistry (IHC) with breast tissue arrays
All breast tissue arrays were purchased from www.alena-
bio.com. BR804a with paired cancer adjacent normal
breast tissue (40 cases/80cores, 4 cases missing), BR20837
included information on TNM (tumor, lymph node,
metastasis) classification, clinical stage and histological
grade (104 cases/208cores, 8 cases missing). The protocols
of immunohistochemistry staining were also downloaded
from www.alenabio.com. Antigen retrieval was performed
by microwave oven method in Tris-EDTA-based solution,
pH 9.0 to about 95 °C, 20 min. Blocking solution was used
to prevent nonspecific binding of antibodies. The sections
were incubated with mouse monoclonal anti-RNF8 anti-
body (Santa Cruz, sc-271462, 1:40 dilution) overnight at
4 °C. GTVision TM III Detection System/Mo&Rb (GK5
00705) was used for detection.
Statistical analysis
The histological diagnosis was made by two pathologists.
SPSS version 17.0 was used for statistical analysis. Com-
parisons between cancers and adjacent normal tissues
were performed using two-sample paired wilcoxon signed
rank test. Association of RNF8 with clinic pathologic fac-
tors using K-independent samples Cruskal-Wallis test. The
differences between two independent groups were analysed
using Student’s t test. P-value < 0.05 was considered to be a
statistically significant difference. Kaplan-Meier survival
analysis for the relationship between survival time and
RNF8 signature in breast cancer was performed using the
online tool (http://kmplot.com/analysis/).
Additional file
Additional file 1: Table S1. RNF8 Immunostaining Pattern Scoring.
Figure S1. Real-time PCR analysis of relative E-cadherin mRNA change in
RNF8-knockdowned MDA-MB-231 cell line. mRNA of GAPDH was used as a
control. Error bars represent mean ± s.d. from three independent experiments;
**p < 0.01. Figure S2. Bioluminescence signals of the cells. Before inoculated
into the mice, the bioluminescence signals of MDA-MB-231-Luc-siCon or
MDA-MB-231-Luc-shRNF8-2 cells were examined by bioluminescence
imaging. Figure S3. Representative immunostaining pattern in the
breast cancer tissues. Images show negative, low and high RNF8
expression respectively. (DOC 3980 kb)
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